Doxofylline-d4

• UNSPSC Description:

  Doxofylline-d4 is the deuterium labeled Doxofylline. Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV[1][2].

• Target Antigen:

  Adenosine Receptor; Isotope-Labeled Compounds; Phosphodiesterase (PDE)

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Solubility:

  10 mM in DMSO

• Smiles:

  C(N1C2=C(N(C)C(=O)N(C)C2=O)N=C1)C3OC(C(O3)([2H])[2H])([2H])[2H]

• Molecular Weight:

  270.28

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10(14):2343-56.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1346599-13-0